PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRisdiplam
Evrysdi(risdiplam)
Evrysdi (risdiplam) is a small molecule pharmaceutical. Risdiplam was first approved as Evrysdi on 2020-08-07. It has been approved in Europe to treat spinal muscular atrophy.
Download report
Favorite
FDA Novel Drug Approvals 2020
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Evrysdi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Risdiplam
Tradename
Company
Number
Date
Products
EVRYSDIGenentechN-213535 RX2020-08-07
1 products, RLD, RS
EVRYSDIGenentechN-219285 RX2025-02-11
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
evrysdiNew Drug Application2025-03-18
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
RISDIPLAM, EVRYSDI, GENENTECH INC
2029-05-27ODE-400
2027-08-07ODE-334
2026-10-03M-270
2025-08-07NCE
2025-05-27NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Risdiplam, Evrysdi, Genentech Inc
115344442038-10-04U-1943
118276462036-01-25U-1943
99697542035-05-11DS, DPU-1943
95869552033-02-08DS, DP
ATC Codes
M: Musculo-skeletal system drugs
— M09: Other drugs for disorders of the musculo-skeletal system in atc
— M09A: Other drugs for disorders of the musculo-skeletal system in atc
— M09AX: Other drugs for disorders of the musculo-skeletal system in atc
— M09AX10: Risdiplam
HCPCS
No data
Clinical
Clinical Trials
30 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Spinal muscular atrophyD009134EFO_0003823G12.1———235
Muscular atrophyD009133—————123
AtrophyD001284—————112
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRisdiplam
INNrisdiplam
Description
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease.
Classification
Small molecule
Drug classsurvival motor neurin SMN1 and SMN2 splicing modulators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1
Identifiers
PDB—
CAS-ID1825352-65-5
RxCUI—
ChEMBL IDCHEMBL4297528
ChEBI ID—
PubChem CID118513932
DrugBankDB15305
UNII ID76RS4S2ET1 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Evrysdi – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,186 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,669 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use